CA3159188A1 - Pyridazinones as parp7 inhibitors - Google Patents
Pyridazinones as parp7 inhibitorsInfo
- Publication number
- CA3159188A1 CA3159188A1 CA3159188A CA3159188A CA3159188A1 CA 3159188 A1 CA3159188 A1 CA 3159188A1 CA 3159188 A CA3159188 A CA 3159188A CA 3159188 A CA3159188 A CA 3159188A CA 3159188 A1 CA3159188 A1 CA 3159188A1
- Authority
- CA
- Canada
- Prior art keywords
- trifluoromethyl
- alkyl
- oxo
- nrc3rd3
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927934P | 2019-10-30 | 2019-10-30 | |
| US62/927,934 | 2019-10-30 | ||
| PCT/US2020/057831 WO2021087025A1 (en) | 2019-10-30 | 2020-10-29 | Pyridazinones as parp7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3159188A1 true CA3159188A1 (en) | 2021-05-06 |
Family
ID=73699388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3159188A Pending CA3159188A1 (en) | 2019-10-30 | 2020-10-29 | Pyridazinones as parp7 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11691969B2 (enExample) |
| EP (1) | EP4051384A1 (enExample) |
| JP (1) | JP7641957B2 (enExample) |
| KR (1) | KR20220109401A (enExample) |
| CN (1) | CN114761086B (enExample) |
| AR (1) | AR120338A1 (enExample) |
| AU (1) | AU2020375821B2 (enExample) |
| CA (1) | CA3159188A1 (enExample) |
| IL (1) | IL292432B1 (enExample) |
| MX (1) | MX2022005216A (enExample) |
| PH (1) | PH12022551013A1 (enExample) |
| TW (1) | TWI902715B (enExample) |
| WO (1) | WO2021087025A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022006A2 (pt) | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| TWI902715B (zh) | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為ｐａｒｐ７抑制劑的嗒酮 |
| CN116157396B (zh) * | 2020-11-27 | 2025-07-18 | 康百达（四川）生物医药科技有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
| US20240166664A1 (en) * | 2021-02-03 | 2024-05-23 | Shanghai Apeiron Therapeutics Company Limited | Triheterocyclic compound, preparation method therefor, and application thereof |
| EP4291560A4 (en) * | 2021-02-09 | 2025-01-15 | Jacobio Pharmaceuticals Co., Ltd. | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS |
| WO2022188889A1 (zh) * | 2021-03-12 | 2022-09-15 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| CN117279917A (zh) * | 2021-05-21 | 2023-12-22 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| WO2022247839A1 (zh) * | 2021-05-25 | 2022-12-01 | 山东轩竹医药科技有限公司 | Parp7抑制剂 |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| WO2023001247A1 (zh) * | 2021-07-21 | 2023-01-26 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| WO2023001296A1 (zh) * | 2021-07-23 | 2023-01-26 | 武汉人福创新药物研发中心有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| WO2023011629A1 (zh) * | 2021-08-06 | 2023-02-09 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| WO2023020479A1 (zh) * | 2021-08-16 | 2023-02-23 | 重庆华森制药股份有限公司 | Parp7抑制剂及其应用 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116444497B (zh) * | 2022-01-14 | 2025-06-24 | 如东凌达生物医药科技有限公司 | 一类哒嗪酮类化合物、制备及其应用 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| WO2023185073A1 (zh) * | 2022-04-01 | 2023-10-05 | 诺沃斯达药业(上海)有限公司 | Parp7抑制剂及其用途 |
| CN117586263B (zh) * | 2022-08-09 | 2026-04-10 | 康百达（四川）生物医药科技有限公司 | 哌嗪衍生物及其在医药上的应用 |
| EP4570249A4 (en) * | 2022-08-09 | 2026-07-22 | Kangbaida Sichuan Biotechnology Co Ltd | USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR |
| TW202416984A (zh) * | 2022-08-17 | 2024-05-01 | 大陸商北京加科思新藥研發有限公司 | 化合物i或其鹽的固體形式 |
| CN117164524B (zh) * | 2022-09-06 | 2026-02-03 | 杭州师范大学 | 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用 |
| WO2024149231A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
| CN118388414A (zh) * | 2023-01-17 | 2024-07-26 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| CN121752568A (zh) * | 2023-08-29 | 2026-03-27 | 康百达（四川）生物医药科技有限公司 | 一种哌嗪衍生物的制备工艺及其中间体 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3255293B2 (ja) | 1997-09-05 | 2002-02-12 | 松下電器産業株式会社 | 蛍光偏光法 |
| WO2002082082A2 (en) | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
| HU227237B1 (en) | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
| GB0301628D0 (en) | 2002-09-19 | 2003-02-26 | Aventis Pharma Inc | Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP) |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP2502918B1 (en) | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
| MX347085B (es) | 2006-12-28 | 2017-04-06 | Abbott Laboratories * | Inhibidores de la poli (adp-ribosa) polimerasa. |
| JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| DK2271626T3 (en) | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| RU2013150102A (ru) | 2011-04-11 | 2015-05-20 | Эббви Инк. | Ингибиторы parp для лечения cipn |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2016116602A1 (en) | 2015-01-23 | 2016-07-28 | Astrazeneca Ab | Treatment of cancer |
| CN106749261A (zh) | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| US12435078B2 (en) | 2017-09-18 | 2025-10-07 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
| GB201717080D0 (en) | 2017-10-18 | 2017-11-29 | Syngenta Participations Ag | Chemical process |
| BR112020022006A2 (pt) | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| WO2021087018A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| TWI902715B (zh) | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為ｐａｒｐ７抑制劑的嗒酮 |
| JP7382261B2 (ja) | 2020-03-19 | 2023-11-16 | 株式会社日立製作所 | 情報処理装置及び方法 |
-
2020
- 2020-10-29 TW TW109137556A patent/TWI902715B/zh active
- 2020-10-29 CA CA3159188A patent/CA3159188A1/en active Pending
- 2020-10-29 US US17/083,442 patent/US11691969B2/en active Active
- 2020-10-29 JP JP2022525496A patent/JP7641957B2/ja active Active
- 2020-10-29 AR ARP200102992A patent/AR120338A1/es unknown
- 2020-10-29 PH PH1/2022/551013A patent/PH12022551013A1/en unknown
- 2020-10-29 WO PCT/US2020/057831 patent/WO2021087025A1/en not_active Ceased
- 2020-10-29 IL IL292432A patent/IL292432B1/en unknown
- 2020-10-29 CN CN202080083214.3A patent/CN114761086B/zh active Active
- 2020-10-29 AU AU2020375821A patent/AU2020375821B2/en active Active
- 2020-10-29 KR KR1020227018075A patent/KR20220109401A/ko not_active Ceased
- 2020-10-29 MX MX2022005216A patent/MX2022005216A/es unknown
- 2020-10-29 EP EP20819919.0A patent/EP4051384A1/en active Pending
-
2023
- 2023-05-12 US US18/196,601 patent/US12617782B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114761086B (zh) | 2025-07-22 |
| EP4051384A1 (en) | 2022-09-07 |
| CN114761086A (zh) | 2022-07-15 |
| PH12022551013A1 (en) | 2023-03-06 |
| US12617782B2 (en) | 2026-05-05 |
| TWI902715B (zh) | 2025-11-01 |
| TW202128653A (zh) | 2021-08-01 |
| JP7641957B2 (ja) | 2025-03-07 |
| WO2021087025A1 (en) | 2021-05-06 |
| KR20220109401A (ko) | 2022-08-04 |
| US11691969B2 (en) | 2023-07-04 |
| MX2022005216A (es) | 2022-06-02 |
| US20240034728A1 (en) | 2024-02-01 |
| IL292432A (en) | 2022-06-01 |
| JP2023501253A (ja) | 2023-01-18 |
| IL292432B1 (en) | 2026-05-01 |
| AR120338A1 (es) | 2022-02-09 |
| AU2020375821A1 (en) | 2022-06-02 |
| AU2020375821B2 (en) | 2026-03-19 |
| US20210130342A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12617782B2 (en) | Pyridazinones as PARP7 inhibitors | |
| AU2024200566B2 (en) | Pyridazinones as PARP7 inhibitors | |
| US20250074897A1 (en) | Pyridazinones as parp7 inhibitors | |
| US20240199584A1 (en) | Kras inhibitors | |
| CA2973760A1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| JP7266592B2 (ja) | ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用 | |
| WO2017071516A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| EA049968B1 (ru) | Пиридазиноны как ингибиторы parp7 | |
| HK40048232A (en) | Pyridazinones as parp7 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241025 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241025 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241025 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241028 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241205 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250403 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250428 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251024 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251028 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251106 |